G3-R represents the most advanced evolution in peptide-based metabolic research. Engineered as a triple-agonist compound, it is designed to engage three critical regulatory pathways—GLP 1, GIP, and glucagon receptors—within energy balance and substrate utilization systems. This multi-pathway activation profile distinguishes G3-R as a next-generation compound in body-composition and metabolic optimization research.
Unlike single- or dual-agonist peptides, G3-R is structured to influence both intake signaling and energy expenditure mechanisms, positioning it as a peak-performance option in advanced peptide development.
Simultaneous activation of GLP 1, GIP, and glucagon receptor pathways
Upregulation of metabolic rate–associated signaling
Enhanced lipid oxidation pathways with preserved structural tissue signaling
High-precision multi-hormonal pathway engagement
Demonstrated efficacy in overcoming metabolic adaptation observed in prior agonist models
G3-R operates through a triple-agonist signaling framework. Activation of GLP 1 and GIP receptor pathways supports regulated energy intake signaling and glucose-related pathway efficiency. Its additional engagement of glucagon receptors differentiates the compound by promoting increased energy expenditure signaling and enhanced lipid mobilization pathways.
This integrated mechanism shifts focus beyond isolated appetite-related pathways toward system-level metabolic modulation. Comparative research data indicate G3-R demonstrates greater overall reductions in adipose-associated markers when evaluated against dual-agonist compounds such as G1-S and G2-T, particularly in models assessing central and visceral fat signaling.
Compound Type: Triple-agonist peptide
Classification: GLP 1 / GIP / Glucagon receptor agonist
Administration Route: Subcutaneous (weekly protocol observed in studies)
Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈
Molecular Weight: 4,731.33 g/mol
Estimated Half-Life: 5–7 days
Development Status: Late-stage clinical research
Research Focus: Metabolic signaling, energy balance modulation, adipose tissue regulation
SlimFit Compounds partners with emerging U.S.-based manufacturers that adhere to strict production, verification, and purity standards. These research-grade formulations are produced using protocols comparable to those employed by major pharmaceutical laboratories, enabling access to high-quality compounds without excessive cost barriers.
This product is intended for research and laboratory use only.
Not for human consumption.
Not intended to diagnose treat cure or prevent any disease.
Information provided is for educational and research reference purposes only and has not been evaluated by the FDA. This compound should only be handled by qualified professionals in appropriate research or laboratory settings.
G3-R represents the most advanced evolution in peptide-based metabolic research. Engineered as a triple-agonist compound, it is designed to engage three critical regulatory pathways—GLP 1, GIP, and glucagon receptors—within energy balance and substrate utilization systems. This multi-pathway activation profile distinguishes G3-R as a next-generation compound in body-composition and metabolic optimization research.
Unlike single- or dual-agonist peptides, G3-R is structured to influence both intake signaling and energy expenditure mechanisms, positioning it as a peak-performance option in advanced peptide development.
Simultaneous activation of GLP 1, GIP, and glucagon receptor pathways
Upregulation of metabolic rate–associated signaling
Enhanced lipid oxidation pathways with preserved structural tissue signaling
High-precision multi-hormonal pathway engagement
Demonstrated efficacy in overcoming metabolic adaptation observed in prior agonist models
G3-R operates through a triple-agonist signaling framework. Activation of GLP 1 and GIP receptor pathways supports regulated energy intake signaling and glucose-related pathway efficiency. Its additional engagement of glucagon receptors differentiates the compound by promoting increased energy expenditure signaling and enhanced lipid mobilization pathways.
This integrated mechanism shifts focus beyond isolated appetite-related pathways toward system-level metabolic modulation. Comparative research data indicate G3-R demonstrates greater overall reductions in adipose-associated markers when evaluated against dual-agonist compounds such as G1-S and G2-T, particularly in models assessing central and visceral fat signaling.
Compound Type: Triple-agonist peptide
Classification: GLP 1 / GIP / Glucagon receptor agonist
Administration Route: Subcutaneous (weekly protocol observed in studies)
Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈
Molecular Weight: 4,731.33 g/mol
Estimated Half-Life: 5–7 days
Development Status: Late-stage clinical research
Research Focus: Metabolic signaling, energy balance modulation, adipose tissue regulation
SlimFit Compounds partners with emerging U.S.-based manufacturers that adhere to strict production, verification, and purity standards. These research-grade formulations are produced using protocols comparable to those employed by major pharmaceutical laboratories, enabling access to high-quality compounds without excessive cost barriers.
This product is intended for research and laboratory use only.
Not for human consumption.
Not intended to diagnose treat cure or prevent any disease.
Information provided is for educational and research reference purposes only and has not been evaluated by the FDA. This compound should only be handled by qualified professionals in appropriate research or laboratory settings.
